fda warning letters compounded semaglutide tirzepatide 2025 Novo Nordisk calls out dangers of GLP-1s in new ad There's lots going on this

If you'd like to shoot me a message in the meantime, I'd love to come back to a few notes from you

By including waist and body composition measurements, researchers say the expanded definition paints a clearer picture of metabolic risk, and reveals millions more at risk for obesity-related disease

As per the regulators Complete Response Letter, the FDA asked for additional evidence to confirm the efficacy and safety of glepaglutide at its proposed dose and recommended that Zealand run another clinical trial to generate these data

Probing the diversity of serotonin neurons

The findings provide reassurance for women who may have been taking these #medications before realizing they were pregnant

But the insights around GLP-1 receptors and the nodose ganglion may be one of the most intriguingand clinically actionablepieces of the puzzle so far